+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 35 Actively Recruiting clinical trials

E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the use of BCMA-targeted positron emission tomographycomputed tomography PETCT scans in patients with multiple myeloma and related plasma cell disorders. This prospective, multicenter diagnostic imaging study aims to visualize and measure BCMA expression throughout the body, helping to detect active disease and its variations. The study focuses on how this imaging method may provide valuable clinical information across different disease states. Participants will receive the 68Ga-labeled BCMA PETCT imaging through an intravenous injection of a BCMA-targeted radiotracer followed by a whole-body scan following a standardized protocol. Imaging results will be compared with biopsy findings when possible to assess accuracy. The study will also explore relationships between PETCT findings and other clinical, laboratory, and imaging markers, including minimal residual disease assessments. Some participants will have blood samples taken to measure circulating soluble BCMA levels, providing additional biological context. During the study, participants will undergo the PETCT imaging and may have biopsies and blood tests as part of assessments. Researchers will analyze imaging findings alongside clinical and laboratory data to understand disease burden and response. Safety of the radiotracer will be monitored for up to 30 days after injection. Follow-up will assess changes in imaging over time and the impact on clinical management. The study is expected to last until December 2027 and includes adults aged 18 to 80 years.

Age: 18Years - 80YearsAll GendersPhase 2Phase 3
5 locations
S

Actively Recruiting

This research aims to evaluate the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease CKD and high blood pressure. The goal is to reduce the risk of serious kidney problems, heart failure events, or cardiovascular death. This is a phase III, international, multicenter, randomized, double-blind, placebo-controlled, event-driven study focused on treatment outcomes. Participants who do not already use SGLT2 inhibitors will first undergo a 4-week dapagliflozin run-in period. After that, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur frequently early on at 2, 4, 8, 16, 34, and 52 weeks post-randomization, then approximately every 4 months. The study will end when a predetermined number of kidney or cardiovascular events occur. During the study, participants will have scheduled visits for assessments including kidney function, heart health, and safety monitoring. If they stop the study treatment early, they will continue on dapagliflozin alone and remain in the trial for follow-up visits. Researchers will measure outcomes such as sustained kidney function decline, kidney failure, heart failure events, cardiovascular death, and all-cause death over up to 37 months. Data collection continues until the study closes, with safety and tolerability closely observed throughout.

Age: 18Years +All GendersPhase 3
771 locations
P

Actively Recruiting

Researchers are conducting a Phase IbIIa clinical trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of IMC-003 injection in adults with pulmonary arterial hypertension PAH who are already receiving background therapy. The trial focuses on patients with WHO Group 1 PAH, including several subtypes such as idiopathic, heritable, and drug-induced PAH. Participants must have symptomatic PAH with specific functional classifications and hemodynamic criteria confirmed by right heart catheterization. Participants will be randomly assigned to receive either IMC-003 or a placebo, injected eight times every three weeks while continuing their stable background PAH treatment. Background therapy includes approved drugs such as endothelin receptor antagonists, PDE-5 inhibitors, sGC stimulators, and prostacyclin analogs. The study is double-blinded and parallel in design, and treatment will last for 24 weeks in both phases of the trial. During the study, participants will undergo various assessments including heart MRI, 6-minute walk distance tests, and blood tests measuring NT-proBNP and other hemodynamic parameters. Researchers will monitor safety, disease progression, and treatment effects throughout the 24-week treatment period. The study also includes ongoing evaluation of symptoms, functional classification, and laboratory markers to understand the impact of IMC-003 in this patient population.

Age: 18Years - 75YearsAll GendersPhase 1Phase 2
29 locations
P

Actively Recruiting

Researchers are evaluating the efficacy and safety of Rocbrutinib monotherapy compared to the investigators choice of BRR2 regimen in patients with relapsed or refractory non-germinal center B-cell-like non-GCB diffuse large B-cell lymphoma DLBCL. This open-label, randomized controlled Phase II clinical study aims to provide new treatment options for patients who have experienced relapse or resistance after prior therapies, including at least one anti-CD20 antibody-containing regimen. Participants are randomly assigned to receive either Rocbrutinib at 200 mg orally once daily until disease progression or unacceptable toxicity, or the investigators choice of combination therapy consisting of Bendamustine and Rituximab BR or Rituximab plus Lenalidomide R2. The BR regimen involves six 28-day cycles of Bendamustine 90 mgm2 IV infusion on Days 1 and 2 and Rituximab 375 mgm2 IV infusion on Day 1 of each cycle, while the R2 regimen includes Rituximab with Lenalidomide at 20 mg orally on Days 1 to 21 of each cycle. Participants will undergo regular assessments including evaluations of overall response rate, complete remission rate, progression-free survival, overall survival, duration and time to response, and safety monitoring up to 24 months, with some outcomes followed for up to five years. Safety is assessed from the first dose until 28 days after the last dose. The total participation duration depends on treatment response and follow-up schedules, with careful monitoring throughout the study to track treatment effects and adverse events.

Age: 18Years +All GendersPhase 2
41 locations
P

Actively Recruiting

Researchers are evaluating a new medicine called YL201 compared to the standard chemotherapy chosen by doctors in people with locally advanced or metastatic esophageal squamous cell carcinoma who have stopped responding to first-line treatment. The goal is to see if YL201 works better and is safer. The study is a large, randomized phase III trial involving multiple hospitals and also investigates how YL201 is processed in the body, immune reactions it might cause, and whether certain biological markers can predict its effects. Participants will be assigned to one of two groups one group receives YL201 alone, given as an intravenous infusion on the first day of each 3-week cycle. The other group receives a chemotherapy drug chosen by their doctor, which may be paclitaxel, docetaxel, or irinotecan, each given intravenously on specific schedules every 3 weeks. The study treatment continues as planned, with monitoring throughout the treatment period. During the study, participants will undergo regular evaluations including scans and laboratory tests to measure how well the treatments are working and to monitor side effects. The main outcome researchers will track is overall survival for up to about 36 months. They will also assess progression-free survival, response rates, duration of response, and adverse events during this time. The study will last until the end of 2028, with ongoing monitoring and data collection.

Age: 18Years +All GendersPhase 3
81 locations
P

Actively Recruiting

Researchers are studying SKB500 in people with advanced solid tumors to understand its safety, how the body processes it, immune response, and effects against tumors. This Phase I clinical trial includes multiple stages dose-escalation, dose-expansion, and indication-expansion phases to evaluate these aspects in detail. Participants will receive SKB500 through an intravenous infusion once every three weeks. The study will monitor how well participants tolerate the treatment, any side effects, and how the drug behaves in the body across the different study phases. During the study, participants will undergo regular assessments to track adverse events, dose-limiting toxicities, and antitumor activity up to three years. Evaluations include measuring drug levels over time, immune responses, and overall safety. Participants will be followed closely throughout the treatment and observation periods to gather comprehensive data.

Age: 18Years - 75YearsAll GendersPhase 1
1 location
P

Actively Recruiting

Researchers are studying the safety and effectiveness of AHB-137 injection in adults with chronic hepatitis B CHB who have low levels of hepatitis B surface antigen HBsAg. This Phase 2, open-label, multicenter study aims to evaluate how well AHB-137 works alongside or without nucleostide analogue NA therapy in this population. Participants receive AHB-137 injections, with some also receiving NA therapy while others do not. The study includes different parts where participants may be treated with AHB-137 combined with NA therapy or AHB-137 alone. Treatment and monitoring continue through multiple weeks, including assessments after stopping all CHB treatments. During the study, participants undergo various tests to measure viral markers such as HBsAg, HBV DNA, and other related indicators, along with quality of life questionnaires. Researchers track the presence of anti-drug antibodies, drug resistance, and treatment-emergent adverse events for up to 60 weeks, including a key evaluation at 24 weeks after stopping all CHB treatment to assess persistent viral suppression.

Age: 18Years - 65YearsAll GendersPhase 2
12 locations
E

Actively Recruiting

Researchers are evaluating the efficacy of claseprubart DNTH103 compared to placebo in adults with chronic inflammatory demyelinating polyneuropathy CIDP. This Phase 3 study aims to assess whether claseprubart can improve outcomes in participants with typical or variant forms of CIDP, including motor or multifocal types. The study is sponsored by Dianthus Therapeutics and involves several treatment periods to carefully measure the drugs impact. The study consists of multiple parts Part A includes an open-label phase lasting up to 13 weeks where participants receive an intravenous loading dose of claseprubart followed by subcutaneous injections every two weeks. Part B is a randomized, double-blind period lasting up to 52 weeks where participants who responded in Part A receive either claseprubart or placebo as subcutaneous injections every two weeks. Eligible participants may then join an optional open-label extension lasting up to 104 weeks receiving claseprubart injections every two weeks. A safety follow-up period of 40 weeks follows to monitor long-term effects. Participants will undergo various assessments throughout the study, including evaluations of neurological function and disease activity using scales such as the Adjusted Inflammatory Neuropathy Cause and Treatment INCAT score, Inflammatory Rasch-built Overall Disability Scale I-RODS, grip strength measurements, and other strength and disability scales. Researchers will also monitor for adverse events, measure serum drug concentrations, and evaluate immune responses. The total participation time may extend over several years, with regular visits for treatment administration, monitoring, and safety follow-up.

Age: 18Years - 75YearsAll GendersPhase 3
201 locations
E

Actively Recruiting

Researchers are evaluating whether tenecteplase helps adults recover from an acute ischemic stroke when given more than 4.5 hours after the person was last seen well. This study focuses on people who had a stroke caused by a clot blocking a brain blood vessel and have imaging showing brain tissue that can still be saved. Participants are excluded if they are planned for a procedure to remove the clot. Participants are randomly placed into two groups. One group receives a single intravenous injection of tenecteplase, while the other group receives standard medical care. The trial compares these treatments to see if tenecteplase improves recovery when given later than the usual 4.5-hour window after stroke onset. Participants stay in the study for about three months, including roughly one week in the hospital. They undergo seven clinical visits or exams, with the last two likely done remotely from home. Doctors assess recovery using a scale that measures disability and dependence in daily life. They also monitor health and any side effects to compare outcomes between the two groups.

Age: 18Years +All GendersPhase 3
257 locations
P

Actively Recruiting

Researchers are evaluating the safety, tolerability, and effectiveness of SHR-4849 injections in adults with advanced solid tumors. This phase I, open-label, multicenter clinical trial aims to find a safe and reasonable dose of SHR-4849 for treating these tumors. The study is sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. and focuses on patients aged 18 to 75 years with confirmed advanced solid tumors and measurable lesions. Participants will receive SHR-4849 as the investigational drug during the dose escalation and dose expansion phases. The study observes each participant for dose-limiting toxicities DLTs within 21 days and monitors adverse events for up to 24 months. After dose escalation, the maximum tolerated dose MTD or maximum administered dose MAD and recommended phase 2 dose RP2D will be determined. The trial does not use a placebo or blinding, and the treatment is given under close medical supervision. Throughout the study, participants will undergo regular evaluations including tumor response assessments using RECIST 1.1 criteria, safety monitoring, and pharmacokinetic testing. Researchers will measure outcomes like objective response rate, disease control rate, duration of response, progression-free survival, and overall survival over periods up to 30 months. Safety follow-up extends for 24 months to track adverse events. The total participation time varies depending on the treatment and follow-up schedules.

Age: 18Years - 75YearsAll GendersPhase 1
1 location

1-10 of 35

1